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Abstract
CD74 is a multifunctional protein and a receptor for Macrophage Migration Inhibitory Factor
(MIF) and MIF-2 / D-dopachrome tautomerase (DDT) cytokines, upregulated in diabetic kid-
ney disease. However, the drivers of CD74 expression and DDT function in kidney cells are
poorly characterized. TWEAK is a proinflammatory cytokine that promotes kidney injury.
We have now identified CD74 gene expression as upregulated in the kidneys in response to
systemic TWEAK administration in mice, and have characterized the in vivo CD74 expres-
sion and the functional consequences in cultured cells. TWEAK administration to mice
resulted in a progressive time-dependent (up to 24h) upregulation of kidney CD74 mRNA
(RT-PCR) and protein (Western blot). Furthermore, the CD74 ligands MIF and DDT were
also upregulated at the protein level 24h after TWEAK administration. Immunohistochemis-
try localized the increased CD74, MIF and DDT expression to tubular cells. In cultured tubu-
lar cells, TWEAK increased CD74 mRNA and protein expression dose-dependently, with a
temporal pattern similar to in vivo. TWEAK-induced CD74 localized to the cell membrane,
where it can function as a cytokine receptor. For the first time, we explored the actions of
DDT in tubular cells and found that DDT amplified the increase in MCP-1 and RANTES
expression in response to TWEAK. By contrast, DDT did not significantly modify TWEAK-
induced Klotho downregulation. In conclusion, TWEAK upregulates CD74 and its ligands
MIF and DDT in renal tubular cells. This may have functional consequences for kidney injury
since DDT amplified the inflammatory response to TWEAK.
Introduction
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a proinflammatory cytokine
of the TNF superfamily that activates the fibroblast growth factor-inducible-14 (Fn14) receptor
[1–3] as reviewed in detail previously [1]. TWEAK actions on intrinsic kidney cells and on
inflammatory cells may contribute to kidney injury. Thus, in cultured tubular cells TWEAK
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induces the expression of inflammatory cytokines, downregulates the expression of the anti-
aging and anti-inflammatory factor Klotho, is mitogenic, and in the presence of sensitizing
agents, promotes apoptosis [1–5]. Increased expression of TWEAK and Fn14 was reported in
human and experimental acute and chronic kidney disease [6,7]. Indeed, the role of TWEAK/
Fn14 in kidney injury has been demonstrated in functional studies using anti-TWEAK antibod-
ies or genetically modified mice in diverse forms of experimental acute kidney injury and
chronic kidney disease (CKD) [8–13]. However, the molecular mechanisms involved in the del-
eterious effect of TWEAK in kidney disease are still incompletely understood.
CD74 (MHC class II invariant chain, Ii) is a transmembrane glycoprotein that regulates
intracellular protein trafficking as a chaperone and is the cognate cell surface receptor for the
cytokines macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase
(D-DT/MIF-2) [14,15], as reviewed in detail previously [16]. During kidney injury, leukocytes
and intrinsic renal cells such as podocytes and tubular epithelial cells express CD74 [17]. In the
kidneys, MIF promotes experimental glomerular injury and cystogenesis [17,18]. Further-
more, CD74 deficient mice are protected from glomerular injury induced by anti-GBM antise-
rum [19]. CD74 modulates B cell, T cell and dendritic cell responses [14,15] and milatuzumab,
an anti-CD74 antibody, has orphan drug status for the treatment of multiple myeloma and
chronic lymphocytic leukemia [20]. In renal cells, MIF activates CD74 to promote a proin-
flammatory response [21]. In this regard, CD74 may modulate tissue injury and homeostasis
beyond its effect on immune regulation.
CD74 expression is increased during tissue injury in diverse organs and in malignancies,
including kidney cancer [16,17,22]. In normal mouse and human kidneys, tubular but not glo-
merular epithelium express low levels of CD74 [21]. CD74 is upregulated in tubular epithelial
cells and/or podocytes during diverse human kidney diseases [18,21,23,24].
While MIF has been implicated in glomerular and tubulointerstitial injury [16,17], very lit-
tle is known about D-dopachrome tautomerase (DDT), a second ligand for CD74, in kidney
disease [16,25]. In addition, the factors regulating CD74 or DDT expression in kidney cells are
poorly characterized. Understanding these factors may help modulate the impact of CD74 or
DDT in kidney injury. We have now explored the regulation of CD74 and DDT expression by
TWEAK in kidney cells and the functional consequences of this regulation.
Material and methods
Animal model
All animal work have been conducted according to national and international guidelines and
was approved by the Fundacion Instituto Investigacion Sanitaria Fundacion Jimenez Diaz ani-
mal research ethics committee. Euthanasia was performed by cervical dislocation.
Studies were conducted in accord with the NIH Guide for the Care and Use of Laboratory
Animals. Female, 12- to 14-week-old C57/BL6 mice from the IIS-Fundacion Jimenez Diaz ani-
mal facilities were administered 0.75 μg TWEAK or saline intraperitoneally and were killed 4
and 24 h after injection (n = 5 per group). The dose of TWEAK was calculated on the basis of
cell culture dose-response experiments for an extracellular volume of 7.5 ml/mouse and was
previously shown to elicit biological responses in vivo [26]. Kidneys were perfused in vivo with
ice-cold saline and processed for immunohistochemistry or immediately frozen for RNA and
protein studies.
Cells and reagents
MCT cells are a cultured line of proximal tubular epithelial cells harvested originally from the
renal cortex of SJL mice and have been extensively characterized [27]. They were cultured in
DDT in tubular cells
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RPMI 1640 (GIBCO, Grand Island, NY, USA), 10% decomplemented fetal bovine serum
(FBS), 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, in 5% CO2 at 37 ˚C
[27]. Recombinant human soluble TWEAK (Millipore, Billerica, MA) was used at 10 to 100
ng/ml, based on prior dose-response experiments [5]. DDT (Prof. Bucala, Yale University
School of Medicine) was used at 10 ng/mL based on prior experience activating the CD74
receptor on renal cells with MIF and on circulating levels of DDT [21]. The NFκB inhibitor
parthenolide (Sigma, St. Louis, MO) was used at 10 μM based on previous dose-responses
studies [28].
Western blot analysis
Tissue and cell samples were homogenized in lysis buffer, separated by 10% or 12% SDS-PAGE
under reducing conditions and transferred to PVDF membranes (Millipore, Bedford, MA,
USA), blocked with 5% skimmed milk in PBS/0.5% v/v Tween 20 for 1 h, and washed with
PBS/Tween [28]. Primary antibodies were rabbit polyclonal anti-CD74 (1:500, Santa Cruz,
CA, USA), anti-MIF (1:500, Santa Cruz, CA, USA) and anti-DDT (1:500, Abcam). Antibodies
were diluted in 5% milk PBS/Tween. Blots were washed with PBS/Tween and subsequently
incubated with appropriate horseradish peroxidase-conjugated secondary antibody (1:2000,
GE Healthcare/Amersham, Aylesbury, UK). After washing, blots were developed with the
chemiluminescence method (ECL). Blots were then re-probed with monoclonal anti- mouse
α-tubulin antibody (1:2000, Sigma) and levels of expression were corrected for minor differ-
ences in loading.
Quantitative reverse transcription-polymerase chain reaction
One μg RNA isolated by Trizol (Invitrogen, Paisley, UK) was reverse transcribed with High
Capacity cDNA Archive Kit and real-time PCR was performed on a ABI Prism 7500 PCR sys-
tem (Applied Biosystems, Foster City, CA) using the DeltaDelta Ct method [28]. Expression
levels are expressed as ratios to GAPDH. Pre-developed primer and probe assays were from
Applied Biosystems.
Immunohistochemistry
Immunohistochemistry was carried out as previously described on paraffin-embedded 5 μm
thick tissue sections [27]. Primary antibodies were rabbit polyclonal anti-CD74 (1:50, Santa
Cruz, CA, USA), anti-DDT (1:100, Abcam) and anti-MIF (1:100, Santa Cruz). Sections were
counterstained with Carazzi‘s hematoxylin. Negative controls included incubation with a non-
specific immunoglobulin of the same isotype as the primary antibody. Sections were subse-
quently incubated with the proximal tubule marker, fluorescein-conjugated tetragonolobus
lotus lectin (1:33, Vector Lab, Peterborough, United Kingdom). Staining was evaluated by a
quantitative scoring system, Image-Pro Plus software (Media Cybernetics, Bethesda, MD) in
10 randomly selected fields (x20) per kidney. Samples were examined in a blinded manner.
Flow cytometry analysis of cell surface CD74 expression
Cells were detached with 2 mM EDTA and 5 x 105 cells were incubated for 30 min at 4˚C with
8 μg/ml rabbit anti-CD74 antibody (Santa Cruz) or control IgG followed by a 30-min 4˚C
incubation with 1:100 FITC secondary antibody (Pharmingen, San Diego, CA) [29]. Mean cell
fluorescence was calculated using Cell Quest Software (Becton Dickinson, Franklin Lakes, NJ).
DDT in tubular cells
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Statistics
Statistical analysis was performed using SPSS 11.0 statistical software (IBM, NY, USA). Results
are expressed as mean ± SEM. Significance at the p<0.05 level was assessed by Student´s t test
for two groups of data and ANOVA for three of more groups with Bonferroni correction.
Results
TWEAK increases CD74 expression in tubular cells in vivo
Systemic TWEAK administration promotes an inflammatory response in the kidneys that is
already evident 4h after TWEAK administration [5]. Increased CD74 expression following
TWEAK administration was observed by qRT-PCR: TWEAK-induced upregulation of kidney
CD74 mRNA was already present at 4 h and peaked at 24 h (Fig 1A). Furthermore, TWEAK-
induced upregulation of CD74 protein was observed at 24 h (Fig 1B). Immunohistochemistry
localized the increased CD74 expression to tubular epithelium (Fig 2A). Specifically, proximal
tubule lectin staining localized CD74 to proximal tubular cells (Fig 2A), although the highest
CD74 expression located to distal tubules (Fig 3). The increased CD74 expression localized
both to the perinuclear area, a typical CD74 expression pattern, and also to the cell membrane
area, where it could serve as a DDT or MIF receptor (Fig 3).
TWEAK increases MIF and DDT expression in tubular cells in vivo
MIF and DDT are the two known ligands for CD74. TWEAK also upregulates kidney MIF
and DDT protein at 24 h in vivo (Fig 4A and 4B). Immunohistochemistry localized the expres-
sion of MIF and DDT to tubular cells (Fig 2B and 2C). Specifically, proximal tubule lectin
staining localized both proteins to proximal tubular cells (Fig 2B and 2C). DDT and MIF were
located on opposite poles of the cell, potentially suggesting secretion to different compart-
ments. Thus, TWEAK upregulated both the two ligands and the receptor within the same cell
compartment (tubular cells) and at the same time point. Under the staining conditions, no
upregulation of CD74, MIF or DDT was apparent in glomeruli (Fig 2A–2C).
TWEAK increases CD74 and DDT expression in cultured tubular cells
Once tubular cells were identified in vivo as expressing CD74 and DDT following TWEAK
stimulation, we assessed TWEAK regulation of CD74 and DDT expression in cultured tubular
cells. In these cells, TWEAK induced upregulation of CD74 and DDT mRNA in a dose-depen-
dent manner (Fig 5A). Similar to the in vivo findings, CD74 mRNA expression increased
progressively over 24h (Fig 5B). TWEAK also increased DDT mRNA in a time-dependent
manner (Fig 5C). Also consistent with the in vivo findings, TWEAK-induced upregulation of
CD74 protein was observed at 24 h (Fig 5D).
The bulk of CD74 is usually confined to the intracellular perinuclear region [30]. In non-
permeabilized tubular cells, flow cytometry assessment of cell surface CD74 confirmed that
TWEAK-induced upregulation of CD74 was associated with increased cell surface CD74 (Fig
5E). At this location, CD74 can function as a receptor for MIF and DDT.
In tubular cells, TWEAK activates several signal transduction pathways that converge at the
transcription factor NF-κB, leading to nuclear translocation of the key component of the
canonical NF-κB activation pathway, NF-κB p65 [5,31,32]. In prior studies, we have shown
that parthenolide inhibits TWEAK-induced NF-κB DNA-binding activity and subsequent
NF-κB p65-dependent gene transcription [5]. In this regard, TWEAK-induced upregulation
of CD74 mRNA expression was abrogated by parthenolide (Fig 5F), indicating that it is a
canonical NF-κB activation–dependent response.
DDT in tubular cells
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TWEAK sensitizes tubular cells to DDT proinflammatory actions
Since TWEAK upregulated the expression of CD74 and DDT in vivo, we explored the func-
tional consequences of this observation. The function of DDT in kidney cells had not been pre-
viously explored. Under basal conditions, DDT had a very mild proinflammatory activity in
cultured tubular cells that did not reach statistical significance (Fig 6A–6C). This may be
Fig 1. TWEAK increases CD74 expression in tubular cells in vivo. A) Quantitative RT-PCR analysis of whole kidney CD74 mRNA in mice 4 h and 24
h after TWEAK or vehicle injection. p<0.005 versus control. B) Whole kidney CD74 protein expression 24 h after TWEAK or vehicle injection.
Quantification of Western blot and representative image. p<0.005 versus control. Data are mean ± SEM of 5 mice per group.
https://doi.org/10.1371/journal.pone.0199391.g001
DDT in tubular cells
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Fig 2. Increased expression of CD74, MIF and DDT following TWEAK administration is localized to tubular cells. A) CD74
immunohistochemistry localized the increased CD74 expression to tubular cells 24 hours after TWEAK or vehicle injection (arrow). B) MIF
and DDT immunohistochemistry localized their increased expression to tubular cells 24 hours after TWEAK or vehicle injection.
Tetragonolobus lotus lectin (green) stains proximal tubular cells and colocalized in tubules with the three proteins. Original magnification x400.
Images representative of 5 animals per group. C) CD74, MIF and DDT quantification expressed as mean mean ± SEM p<0.03 versus control,
p<0.003 versus control.
https://doi.org/10.1371/journal.pone.0199391.g002
DDT in tubular cells
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related to the low constitutive cell surface CD74 expression (Fig 5D). However, increasing
CD74 expression by pre-stimulating with TWEAK resulted in a large increase in the expres-
sion of MCP-1 and RANTES mRNA in response to DDT, well above the expression elicited by
either DDT or TWEAK alone (Fig 6A and 6B). By contrast, DDT did not influence the expres-
sion of Klotho mRNA and did not significantly modify TWEAK-induced Klotho downregula-
tion (Fig 6C).
Discussion
The main findings are that TWEAK promotes the expression of CD74 and DDT in tubular
cells, and increases the availability of CD74 at the cell surface, thus sensitizing to the proin-
flammatory action of DDT. This information is useful to design therapeutic strategies aimed at
Fig 3. CD74 localization to perinuclear and cell membrane areas in distal tubular cells. CD74 immunohistochemistry
localized the increased CD74 expression to tubular cells 24 hours after TWEAK injection to perinuclear (arrows) and cell
membrane areas (arrowheads). Original magnification x400.
https://doi.org/10.1371/journal.pone.0199391.g003
DDT in tubular cells
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modulating CD74 expression both in kidney disease and outside the kidney, and as well as to
design strategies to protect the kidneys from the therapeutic use of anti-CD74 antibodies, as
discussed below.
Functional preclinical in vivo studies have shown that TWEAK is a key mediator of several
forms of kidney injury [1]. However, the molecular mediators recruited by TWEAK remain
poorly understood. CD74 has several functions, including being a receptor for MIF and DDT
[16,17]. We have centered the study on persistent (24h) changes in kidney gene expression fol-
lowing TWEAK administration. At this point, some mRNA expression changes have already
returned to baseline, as it is the case for MCP1 [5]. However, we now show that the expression
of CD74 and its ligands MIF and DDT was persistently increased suggesting that TWEAK is
one of the drivers of their increased expression in kidney disease. MIF expression is increased
in progressive renal injury due to glomerulonephritis and renal transplant rejection [21,33–
35]. MIF promoted podocyte injury and MIF targeting was protective in experimental glomer-
ular disease [19,33]. This is most likely mediated by CD74 activation since CD74 targeting was
also protective [19]. DDT, a member of the MIF cytokine superfamily, was recently described
as a more selective CD74 agonist than MIF because it lacks the pseudo(E)LR motif present in
MIF that mediates interaction with CXCR2 and CXCR4 [36] DDT was previously considered
an enzyme that catalyzes the tautomerization and decarboxylation of D-dopachrome to
5,6-dihydroxyindole [37,38]. DDT is constitutively expressed in several mammalian tissues
and is stored in macrophages [25,36,39]. As MIF, DDT may also be involved in regulating pro-
inflammatory signaling events. DDT levels are elevated in septic, burn and cancer patients cor-
relating with disease severity and clinical outcome [36,40]. However, DDT expression by kid-
ney cells had not been previously described. For the first time, we have observed increased
Fig 4. TWEAK increases kidney MIF and DDT protein levels in vivo. A) Whole kidney MIF and B) DDT protein
expression 24 hours after TWEAK or vehicle injection. Quantification of Western blot and representative image.
p<0.01 versus control. Data are mean ± SEM of 5 mice per group.
https://doi.org/10.1371/journal.pone.0199391.g004
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DDT expression by tubular cells in response to the systemic administration of a proinflamma-
tory cytokine. In experimental endotoxemia, serum DDT levels are increased with a similar
than MIF, and both proteins were detectable at similar concentration [36,41]. Thus, the DDT
concentration used in the present report is clinically relevant, since circulating serum DDT
Fig 5. TWEAK increases CD74 and DDT expression in cultured tubular cells. A) Dose-response of CD74 mRNA
induction at 3h. mRNA expression was assessed by qRT-PCR. p<0.01 vs control, p<0.001 vs vehicle control. B)
Time-course. Cells were stimulated with 10 ng/mL TWEAK and CD74 mRNA expression was assessed by qRT-PCR.
p<0.002 vs control. C) Time-course. Cells were stimulated with 10 ng/mL TWEAK and DDT mRNA expression was
assessed by qRT-PCR. p<0.01 vs control. D) Time-course. Cells were stimulated with 10 ng/mL TWEAK and
CD74 protein in whole cell lysates was assessed by Western blot. p<0.03 vs control. E) Flow cytometry of non-
permeabilized tubular cells showed that CD74 expression is increased in the cell surface 24 h after 10 ng/mL TWEAK
stimulation as compared to vehicle control. IgG denotes cell stained with non-immune IgG. Control and TWEAK
samples were stained with anti-CD74 antibody. F) Cells were stimulated with 10 ng/mL TWEAK for 3 hours.
TWEAK-induced CD74 mRNA expression was prevented by parthenolide. p<0.002 vs control; p<0.007 vs
TWEAK. Data are mean ± SEM of four independent experiments.
https://doi.org/10.1371/journal.pone.0199391.g005
DDT in tubular cells
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has been described to range from 6 ng/ml in healthy individuals to 30 ng/ml under inflamma-
tory conditions [36]. DDT blockade protected from lethal endotoxemia [16,36] and DDT
binding to CD74/CD44 activates downstream pro-inflammatory intracellular pathways such
as ERK1/2 MAPK signaling, AMP-activated protein kinase (AMPK), NFκB and β-catenin
pathways in B cells, T cells and macrophages [16,42,43]. These pro-inflammatory actions are
consistent with those observed in tubular cells in the present report. However, DDT binding
to CD74 in liver and heart protects from ischemia-reperfusion and metabolic liver injury
through activation of the AMPK pathway [44,45]. In this regard, DDT was recently reported
to improve recovery of injured epithelial cells following kidney ischemia reperfusion [46].
Fig 6. TWEAK sensitizes to DDT proinflammatory actions in tubular cells. Cells were stimulated with 10 ng/mL TWEAK for 3 hours and then with 10 ng/mL
DDT for 24 hours. A) MCP-1 and B) RANTES mRNA was increased after DDT stimulation in cells pretreated with TWEAK. C) Under the same experimental
conditions, Klotho mRNA was downregulated after TWEAK stimulation but addition of DDT had no statistically significant effect over TWEAK alone.
Expression of mRNA was assessed by real time RT-PCR. p<0.02 vs control, p<0.05 vs DDT. Mean ± SEM of four independent experiments.
https://doi.org/10.1371/journal.pone.0199391.g006
DDT in tubular cells
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There is limited information on the regulation of CD74 expression in renal cells. Abnor-
mally high concentrations of certain metabolites (e.g. glucose and lyso-Gb3), TNF and inter-
feron-γ increased CD74 expression in renal cells [21,47,48]. The present findings add
TWEAK to the set of inflammatory cytokines that upregulate CD74 expression in kidney
cells. The main site of CD74 expression is the perinuclear area, as observed in AKI immuno-
histochemistry. However, CD74 is also present at the cell surface as clearly demonstrated by
flow cytometry in cultured tubular cells in presence of TWEAK and as also suggested by
immunohistochemistry. Regulation of cell surface CD74 expression may have therapeutic
consequences for the clinical use of agents currently in clinical development. The anti-CD74
antibody hLL1 milatuzumab, has received orphan drug status for the hematologic malignan-
cies multiple myeloma and chronic lymphocytic lymphoma [49,50]. Milatuzumab binds to
CD74, facilitating internalization of the antibody-CD74 complex, this is used to deliver con-
jugated antitumoral agents inside tumor cells with high CD74 expression, but not to normal
cells with low CD74 levels [51]. Milatuzumab behaves as a CD74 antagonist, but activates
antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity
(CMC). Additionally, internalized toxins may kill tumor cells. However, nephrotoxicity is a
potential complication of antitumoral anti-CD74 therapy, if kidney cells express high CD74
levels as observed in patients with kidney disease. As a clinical implication of the present
findings, a state of systemic activation of the TWEAK/Fn14 system, exemplified by the sys-
temic injection of TWEAK, may be associated to increased kidney CD74 expression, poten-
tially sensitizing to cell death induced by milatuzumab and to nephrotoxicity. This may be of
special concern for one of the indications under study, multiple myeloma, which frequently
causes kidney disease. Unraveling the factors determining increased kidney cell expression
of CD74 may help to design strategies to protect parenchymal cells from the toxicity of
CD74 targeting anti-tumor therapies. Additionally, by localizing the expression of both
ligands and the receptor, it may help unravelling the interactions between these molecules at
the kidney level. Immunohistochemistry suggests potential secretion of MIF and DDT into
differential compartments. MIF is localized mainly in the basolateral tubular cell pole,
suggesting that it may be secreted to the interstitium, were it may interact with interstitial
fibroblasts, leukocytes and tubular cells, while DDT is mainly found in the luminal pole, sug-
gesting that it may contribute to signaling between different nephron segments, since as
MIF, it was mainly found in proximal tubules, while distal tubules expressed high amounts
of CD74.
The present findings may have clinical implications beyond kidney disease. Thus, CD74
plays a role in diverse diseases, either as a promoter of disease (e.g. glomerulonephritis) [19],
as a protective molecule (e.g. liver fibrosis) [52] or as a therapeutic target that allows selective
destruction of a tumor cell population (e.g. myeloma cells) [50]. In addition, CD74, interacts
with amyloid precursor protein (APP), reducing the levels of beta amyloid peptides, proba-
bly by interacting with and derailing normal trafficking of APP [53]. Indeed, CD74 gene
transfer reduced β-amyloidosis and improved cognitive function in a mouse model of Alz-
heimer’s disease [54]. A better understanding of the drivers of CD74 expression may help to
design therapeutic strategies aimed at modulating CD74 levels in the above mentioned
conditions.
In conclusion, TWEAK upregulates CD74 and its ligands MIF and DDT in renal tubular
cells in culture and in vivo. This may have functional consequences for kidney injury since
DDT, at concentrations found in the circulation of inflamed patients, amplified the inflamma-
tory response to TWEAK. In this regard, the present findings support the concept that DDT is
a new player in tubular cell inflammatory responses.
DDT in tubular cells
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